Benign Prostatic Hyperplasia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Benign Prostatic Hyperplasia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Aug 2019 Transparency Market Research Healthcare220 Pages Price :
$ 5795

Benign Prostatic Hyperplasia Treatment Market - Scope of the Study

Transparency Market Research (TMR), in its recently published research report, quantifies the growth of the benign prostatic hyperplasia treatment market during the forecast period of 2019-2027. This exclusive research report on the global benign prostatic hyperplasia treatment market offers a detailed overview of the benign prostatic hyperplasia treatment market, uncovering significant aspects and segmentations based on numerous parameters. This comprehensive research report also talks about the research methodologies being adopted in order to estimate precise market numbers. This detailed business guide also includes relevant charts and tables, in order to enable stakeholders get an incisive outlook of the benign prostatic hyperplasia treatment market for the forecast period.

This statistical business report analyzes, at length, crucial insights obtained by this exclusive study. With the aid of rare and distinguished insights enumerated in this comprehensive research report, stakeholders in the benign prostatic hyperplasia treatment market can form business growth strategies to gain an upper hand over their competitors. Various factors accounted for the benign prostatic hyperplasia treatment market’s upward growth trajectory are discussed at length in this research report. Additionally, the research report identifies and explains the key drivers, threats, restraints, and opportunities present in the benign prostatic hyperplasia treatment market.

This broad study of the global benign prostatic hyperplasia treatment market assesses the growth drivers and restraints at length. This exhaustive study of important factors can aid market players in understanding the challenges present in the benign prostatic hyperplasia treatment market during the forecast period of 2019-2027. The detailed research report gauges the bargaining power of buyers and suppliers, threats arising from new market entrants and substitutes, and the degree of competition present in the benign prostatic hyperplasia treatment market. Influence exerted on the benign prostatic hyperplasia treatment market by the government policies is also discussed in this research report.

Benign Prostatic Hyperplasia Treatment Market - Segmentation

This comprehensive research report encompasses the technological advancements and recent trends to gain a better perspective of the growth of the benign prostatic hyperplasia treatment market. In order to aid market players in having a precise market approach, our analysts have bifurcated the benign prostatic hyperplasia treatment market into key segments - treatment, end user, and region. Key segments of the benign prostatic hyperplasia treatment market are as mentioned below:

Benign Prostatic Hyperplasia Treatment Market - Key Questions Answered

This comprehensive research report analyzes and answers crucial questions related to the growth of the benign prostatic hyperplasia treatment market during the forecast period. Some of the key questions answered in this study are as follows:

  • What are the key developments and important market shifts expected to be observed in the benign prostatic hyperplasia treatment market during the forecast period of 2019-2027?
  • What are the key strategies followed by market participants functioning in the benign prostatic hyperplasia treatment market?
  • What are some of the important recent developments that the new market participants should look at?
  • Which treatment will be the top-selling one in the benign prostatic hyperplasia treatment market?

Benign Prostatic Hyperplasia Treatment Market - Research Methodology

The research approach taken by analysts at Transparency Market Research (TMR) includes a robust methodology for obtaining key insights into the benign prostatic hyperplasia treatment market for the forecast period of 2019-2027. Interviews were conducted with important market participants, opinion leaders, vendors, distributors, and industry experts. In addition to this, a detailed secondary study of company websites, industry associations, marketing collaterals, and government statistics is carried out.

1. Preface 
1.1. Report Scope and Market Segmentation 
1.2. Research Highlights

2. Assumptions and Research Methodology 
2.1. Assumptions and Acronyms Used
2.2. Research Methodology

3. Executive Summary
3.1. Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027
3.2. Global Benign Prostatic Hyperplasia Treatment Market: Market Snapshot

4. Market Overview
4.1. Global Benign Prostatic Hyperplasia Treatment Market: Treatment Overview 
4.2. Global Benign Prostatic Hyperplasia Treatment Market: Key Industry Developments
4.3. Market Dynamics
4.4. Drivers and Restraints Snapshot Analysis
4.5. Drivers
4.5.1. Increasing Aging Men Population All Over the World
4.5.2. Expanding Patient Pool Due to Other Risk Factors
4.6. Restraints
4.6.1. Insufficient Healthcare Facilities and Unawareness of BPH Condition
4.6.2. Patent Expiration of Benign Prostatic Hyperplasia Drugs
4.7. Opportunities
4.8. Global Benign Prostatic Hyperplasia Treatment Market Revenue Projections (US$ Mn), 2017–2027

5. Key Insights
5.1. Clinical Trial Pipeline Analysis
5.2. U.S. Prevalence of Benign Prostatic Hyperplasia
5.3. Re-imbursement Scenario
5.4. Key Merger and Acquisitions
5.5. Number of Surgeries (Unit Procedures) Performed, 2018
5.6. Competitive Market Share Analysis, by Company, 2018
5.7. Average Cost of Benign Prostatic Hyperplasia Treatment 
5.8. Product/Brand Analysis - 2018
5.8.1. Urolift
5.8.2. Rezum

6. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Treatment
6.1. Introduction
6.2. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
6.2.1. Drug Class
6.2.1.1. Alpha-blockers
6.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
6.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
6.2.1.4. Others
6.2.2. Minimally Invasive Surgeries
6.2.2.1. Transurethral Resection of the Prostate (TURP)
6.2.2.2. Transurethral Incision of the Prostate (TUIP)
6.2.2.3. Robotic Surgeries
6.2.2.4. Transurethral Microwave Thermotherapy (TUMT) 
6.2.2.5. Prostatic Urethral Lift
6.2.2.6. Others
6.2.3. Laser Therapy
6.2.4. Others
6.3. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Treatment
6.4. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment

7. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by End-user
7.1. Introduction
7.2. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
7.2.1. Hospitals
7.2.2. Ambulatory Surgical Centers
7.2.3. Specialty Clinics
7.2.4. Others
7.3. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by End-user
7.4. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user

8. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Region
8.1. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Region, 2017–2027 
8.1.1. North America
8.1.2. Europe
8.1.3. Asia Pacific
8.1.4. Latin America
8.1.5. Middle East & Africa
8.2. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Region
8.3. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Region

9. North America Benign Prostatic Hyperplasia Treatment Market Analysis
9.1. North America Benign Prostatic Hyperplasia Treatment Market 
9.2. North America Benign Prostatic Hyperplasia Treatment Market Overview
9.3. North America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
9.3.1. Drug Class
9.3.1.1. Alpha-blockers
9.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
9.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
9.3.1.4. Others
9.3.2. Minimally Invasive Surgeries
9.3.2.1. Transurethral Resection of the Prostate (TURP)
9.3.2.2. Transurethral Incision of the Prostate (TUIP)
9.3.2.3. Robotic Surgeries
9.3.2.4. Transurethral Microwave Thermotherapy (TUMT) 
9.3.2.5. Prostatic Urethral Lift 
9.3.2.6. Others
9.3.3. Laser Therapy
9.3.4. Others
9.3.5. 
9.4. North America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
9.4.1. Hospitals
9.4.2. Ambulatory Surgical Centers
9.4.3. Specialty Clinics
9.4.4. Others
9.5. North America Benign Prostatic Hyperplasia Treatment Market Forecast, by Country
9.5.1. U.S.
9.5.2. Canada
9.6. North America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis 
9.6.1. By Treatment
9.6.2. By End-user
9.6.3. By Country

10. Europe Benign Prostatic Hyperplasia Treatment Market Analysis
10.1. Europe Benign Prostatic Hyperplasia Treatment Market 
10.2. Europe Benign Prostatic Hyperplasia Treatment Market Overview
10.3. Europe Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
10.3.1. Drug Class
10.3.1.1. Alpha-blockers
10.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
10.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
10.3.1.4. Others
10.3.2. Minimally Invasive Surgeries
10.3.2.1. Transurethral Resection of the Prostate (TURP)
10.3.2.2. Transurethral Incision of the Prostate (TUIP)
10.3.2.3. Robotic Surgeries
10.3.2.4. Transurethral Microwave Thermotherapy (TUMT) 
10.3.2.5. Prostatic Urethral Lift 
10.3.2.6. Others
10.3.3. Laser Therapy
10.3.4. Others
10.4. Europe Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
10.4.1. Hospitals
10.4.2. Ambulatory Surgical Centers
10.4.3. Specialty Clinics
10.4.4. Others
10.5. Europe Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
10.5.1. U.K.
10.5.2. France
10.5.3. Germany
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6. Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis 
10.6.1. By Treatment
10.6.2. By End-user
10.6.3. By Country/Sub-region

11. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Analysis
11.1. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Key Findings
11.2. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Overview
11.3. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
11.3.1. Drug Class
11.3.1.1. Alpha-blockers
11.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
11.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
11.3.1.4. Others
11.3.2. Minimally Invasive Surgeries
11.3.2.1. Transurethral Resection of the Prostate (TURP)
11.3.2.2. Transurethral Incision of the Prostate (TUIP)
11.3.2.3. Robotic Surgeries
11.3.2.4. Transurethral Microwave Thermotherapy (TUMT) 
11.3.2.5. Prostatic Urethral Lift 
11.3.2.6. Others
11.3.3. Laser Therapy
11.3.4. Others
11.4. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
11.4.1. Hospitals
11.4.2. Ambulatory Surgical Centers
11.4.3. Specialty Clinics
11.4.4. Others
11.5. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
11.5.1. China
11.5.2. India
11.5.3. Japan
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis 
11.6.1. By Treatment
11.6.2. By End-user
11.6.3. By Country/Sub-region

12. Latin America Benign Prostatic Hyperplasia Treatment Market Analysis
12.1. Latin America Benign Prostatic Hyperplasia Treatment Market Key Findings
12.2. Latin America Benign Prostatic Hyperplasia Treatment Market Overview
12.3. Latin America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
12.3.1. Drug Class
12.3.1.1. Alpha-blockers
12.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
12.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
12.3.1.4. Others
12.3.2. Minimally Invasive Surgeries
12.3.2.1. Transurethral Resection of the Prostate (TURP)
12.3.2.2. Transurethral Incision of the Prostate (TUIP)
12.3.2.3. Robotic Surgeries
12.3.2.4. Transurethral Microwave Thermotherapy (TUMT) 
12.3.2.5. Prostatic Urethral Lift
12.3.2.6. Others
12.3.3. Laser Therapy
12.3.4. Others
12.4. Latin America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
12.4.1. Hospitals
12.4.2. Ambulatory Surgical Centers
12.4.3. Specialty Clinics
12.4.4. Others
12.5. Latin America Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis 
12.6.1. By Treatment
12.6.2. By End-user
12.6.3. By Country/Sub-region

13. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Analysis
13.1. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market 
13.2. Benign Prostatic Hyperplasia Treatment Market Overview
13.3. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
13.3.1. Drug Class
13.3.1.1. Alpha-blockers
13.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
13.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
13.3.1.4. Others
13.3.2. Minimally Invasive Surgeries
13.3.2.1. Transurethral Resection of the Prostate (TURP)
13.3.2.2. Transurethral Incision of the Prostate (TUIP)
13.3.2.3. Robotic Surgeries
13.3.2.4. Transurethral Microwave Thermotherapy (TUMT) 
13.3.2.5. Prostatic Urethral Lift
13.3.2.6. Others
13.3.3. Laser Therapy
13.3.4. Others
13.4. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
13.4.1. Hospitals
13.4.2. Ambulatory Surgical Centers
13.4.3. Specialty Clinics
13.4.4. Others
13.5. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis 
13.6.1. By Treatment
13.6.2. By End-user
13.6.3. By Country/Sub-region

14. Competitive Landscape (Pharmaceutical Companies)
14.1. Company Profiles
14.1.1. Abbott
14.1.1.1. Overview (HQ, Employee Strength, Business Segments)
14.1.1.2. Financials
14.1.1.3. Recent Developments
14.1.1.4. Strategy
14.1.2. Allergan plc
14.1.2.1. Overview (HQ, Employee Strength, Business Segments)
14.1.2.2. Financials
14.1.2.3. Recent Developments
14.1.2.4. Strategy
14.1.3. Astellas Pharma, Inc.
14.1.3.1. Overview (HQ, Employee Strength, Business Segments)
14.1.3.2. Financials
14.1.3.3. Recent Developments
14.1.3.4. Strategy
14.1.4. Asahi Kasei Corporation
14.1.4.1. Overview (HQ, Employee Strength, Business Segments)
14.1.4.2. Financials
14.1.4.3. Recent Developments
14.1.4.4. Strategy
14.1.5. Boehringer Ingelheim GmbH 
14.1.5.1. Overview (HQ, Employee Strength, Business Segments)
14.1.5.2. Financials
14.1.5.3. Recent Developments
14.1.5.4. Strategy
14.1.6. GlaxoSmithKline plc
14.1.6.1. Overview (HQ, Employee Strength, Business Segments)
14.1.6.2. Financials
14.1.6.3. Recent Developments
14.1.6.4. Strategy
14.1.7. Pfizer, Inc.
14.1.7.1. Overview (HQ, Employee Strength, Business Segments)
14.1.7.2. Financials
14.1.7.3. Recent Developments
14.1.7.4. Strategy
14.1.8. Sanofi
14.1.8.1. Overview (HQ, Employee Strength, Business Segments)
14.1.8.2. Financials
14.1.8.3. Recent Developments
14.1.8.4. Strategy
14.1.9. Teva Pharmaceutical Industries Ltd.
14.1.9.1. Overview (HQ, Employee Strength, Business Segments)
14.1.9.2. Financials
14.1.9.3. Recent Developments
14.1.9.4. Strategy
14.1.10. Merck & Co., Inc.
14.1.10.1. Overview (HQ, Employee Strength, Business Segments)
14.1.10.2. Financials
14.1.10.3. Recent Developments
14.1.10.4. Strategy

15. Competitive Landscape (Medical Devices/Service Provider Organizations)
15.1. Company Profiles
15.1.1. Boston Scientific Corporation
15.1.1.1. Overview (HQ, Employee Strength, Business Segments)
15.1.1.2. Financials
15.1.1.3. Recent Developments
15.1.1.4. Strategy
15.1.2. Teleflex Incorporated
15.1.2.1. Overview (HQ, Employee Strength, Business Segments)
15.1.2.2. Financials
15.1.2.3. Recent Developments
15.1.2.4. Strategy
15.1.3. Endo International plc
15.1.3.1. Overview (HQ, Employee Strength, Business Segments)
15.1.3.2. Financials
15.1.3.3. Recent Developments
15.1.3.4. Strategy
15.1.4. Urologix, LLC
15.1.4.1. Overview (HQ, Employee Strength, Business Segments)
15.1.4.2. Financials
15.1.4.3. Recent Developments
15.1.4.4. Strategy
15.1.5. LISA Laser
15.1.5.1. Overview (HQ, Employee Strength, Business Segments)
15.1.5.2. Financials
15.1.5.3. Recent Developments
15.1.5.4. Strategy
15.1.6. Olympus Corporation
15.1.6.1. Overview (HQ, Employee Strength, Business Segments)
15.1.6.2. Financials
15.1.6.3. Recent Developments
15.1.6.4. Strategy

List of Table

List of Tables

TABLE 1 Prostate Cancer Therapeutics : Pipeline Analysis – Phase III (1/2)
TABLE 2 Prostate Cancer Therapeutics : Pipeline Analysis – Phase III (2/2)
TABLE 3 Prostate Cancer Therapeutics : Pipeline Analysis – Phase II (1/2)
TABLE 4 Prostate Cancer Therapeutics : Pipeline Analysis – Phase II (2/2)
TABLE 5 Prostate Cancer Therapeutics : Pipeline Analysis – Phase I
TABLE 6 2015 Patient Population Break Down
TABLE 7 Number of Surgeries (Unit Procedures) Performed in United States (2018)
TABLE 8 Summary of Current BPH Treatments in U.S. 
TABLE 9 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 10 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017–2027
TABLE 11 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017–2027
TABLE 12 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2027
TABLE 13 Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2016–2026
TABLE 14 North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country, 2016–2026
TABLE 15 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 16 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017–2027
TABLE 17 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017–2027
TABLE 18 North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2016–2026
TABLE 19 Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 20 Europe Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 21 Europe Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017–2027
TABLE 22 Europe Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017–2027
TABLE 23 Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
TABLE 24 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 25 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 26 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017–2027
TABLE 27 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017–2027
TABLE 28 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
TABLE 29 Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 30 Latin America Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 31 Latin America Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017–2027
TABLE 32 Latin America Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017–2027
TABLE 33 Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
TABLE 34 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 35 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 36 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017–2027
TABLE 37 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017–2027
TABLE 38 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

List of Chart

List of Figures

FIG. 1 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, 2017–2027
FIG. 2 Global Benign Prostatic Hyperplasia Treatment Market Value Share, by Treatment, 2018
FIG. 3 Global Benign Prostatic Hyperplasia Treatment Market Value Share, by Drug Class, 2018
FIG. 4 Global Benign Prostatic Hyperplasia Treatment Market Value Share, by End-user, 2018
FIG. 5 Global Benign Prostatic Hyperplasia Treatment Market Value Share, by Minimally Invasive Surgery, 2018
FIG. 6 Global Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
FIG. 7 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Drug Class, 2017–2027
FIG. 8 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Minimally Invasive Surgeries, 2017–2027
FIG. 9 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Laser Therapy, 2017–2027
FIG. 10 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Others, 2017–2027
FIG. 11 Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment, 2019–2027
FIG. 12 Global Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
FIG. 13 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Hospitals, 2017–2027
FIG. 14 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Ambulatory Surgical Centers, 2017–2027
FIG. 15 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Specialty Clinics, 2017–2027
FIG. 16 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Others, 2017–2027
FIG. 17 Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user, 2019–2027
FIG. 18 Global Benign Prostatic Hyperplasia Treatment Market Value Share (%), by Region, 2018 and 2026
FIG. 19 Global Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Region, 2018–2026
FIG. 20 North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
FIG. 21 North America Benign Prostatic Hyperplasia Treatment Market Value Share, by Country, 2017 and 2026
FIG. 22 North America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country, 2018–2026
FIG. 23 North America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2017 and 2026
FIG. 24 North America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2018–2026
FIG. 25 North America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2017 and 2026
FIG. 26 North America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2018–2026
FIG. 27 Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019–2027
FIG. 28 Europe Benign Prostatic Hyperplasia Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
FIG. 29 Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 30 Europe Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
FIG. 31 Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2019–2027
FIG. 32 Europe Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
FIG. 33 Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2019–2027
FIG. 34 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019–2027
FIG. 35 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
FIG. 36 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 37 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
FIG. 38 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2019–2027
FIG. 39 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
FIG. 40 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2019–2027
FIG. 41 Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019–2027
FIG. 42 Latin America Benign Prostatic Hyperplasia Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
FIG. 43 Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 44 Latin America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
FIG. 45 Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2019–2027
FIG. 46 Latin America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
FIG. 47 Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2019–2027
FIG. 48 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019–2027
FIG. 49 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
FIG. 50 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 51 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
FIG. 52 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2019–2027
FIG. 53 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
FIG. 54 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2019–2027
FIG. 55 Global Benign Prostatic Hyperplasia Treatment Devices Market Share Analysis, by Company, 2018
FIG. 56 GlaxoSmithKline plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2018
FIG. 57 GlaxoSmithKline plc. R&D Expenses and Selling, General and Administration Expenses (US$ Bn) - Company Level, 2015–2018
FIG. 58 GlaxoSmithKline plc. Breakdown of Net Sales, by Region/Country (Company Level), 2018
FIG. 59 GlaxoSmithKline plc. Breakdown of Net Sales, by Business Segment (Overall Company Level), 2018
FIG. 60 Sanofi R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2014–2017
FIG. 61 Sanofi Breakdown of Net Sales (%), by Region/Country, 2018
FIG. 62 Sanofi Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2018
FIG. 63 Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018
FIG. 64 Pfizer, Inc. Breakdown of Net Sales, by Region/Country, 2018
FIG. 65 Pfizer, Inc. R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2015–2018
FIG. 66 Pfizer, Inc. Breakdown of Net Sales, by Business Segment (%), 2018
FIG. 67 Teva Pharmaceutical Industries Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
FIG. 68 Teva Pharmaceutical Industries Ltd. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
FIG. 69 Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region, 2018
FIG. 70 Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Operating Segment, 2017
FIG. 71 Abbott Laboratories Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2018
FIG. 72 Abbott Laboratories R&D Intensity and Sales & Marketing Intensity – Company Level, 2016–2018
FIG. 73 Abbott Laboratories Breakdown of Net Sales, by Segment, 2018
FIG. 74 Abbott Breakdown of Net Sales (%), by Country/Sub-region, 2018
FIG. 75 Allergan plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018
FIG. 76 Allergan plc Breakdown of Net Sales (%), by Geography, 2018
FIG. 77 Allergan plc R&D Expenses and Marketing & Sales Intensity (%) 2016–2018
FIG. 78 Allergan plc Breakdown of Net Sales (%), by Business Segment, 2018
FIG. 79 Endo Pharmaceuticals, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2018
FIG. 80 Endo Pharmaceuticals, Inc. Breakdown of Net Sales (%), by Region, 2016
FIG. 81 Endo Pharmaceuticals, Inc. total Acquisition-related and Integration Items, Expenses in 2016–2018
FIG. 82 Endo Pharmaceuticals, Inc. Breakdown of Net Sales (%), by Specialty Products, 2018
FIG. 83 Boehringer Ingelheim GmbH Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2018
FIG. 84 Boehringer Ingelheim GmbH Breakdown of Net Sales, by Region (Company Level), 2018
FIG. 85 Boehringer Ingelheim GmbH Breakdown of Net Sales, by Business and Business Segment Level, 2017
FIG. 86 Boehringer Ingelheim GmbH R&D Expenditure (US$ Mn), 2016–2018
FIG. 87 Merck & Co., Inc. Break-up of Net Sales, by Region, 2017
FIG. 88 Merck & Co., Inc. Pharmaceutical Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018
FIG. 89 Merck & Co., Inc. R&D Intensity (%) - Company Level or Segment Level, 2014–2017
FIG. 90 Asahi Kasei Corporation Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
FIG. 91 Asahi Kasei Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
FIG. 92 Asahi Kasei Corporation Breakdown of Net Sales (%), by Business Segment, 2018
FIG. 93 Astellas Pharma, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2018
FIG. 94 Astellas Pharma, Inc. Breakdown of Net Sales (%), by Region, 2016
FIG. 95 Astellas Pharma, Inc. R&D expenses (US$ Bn) in 2016–2018
FIG. 96 Astellas Pharma, Inc. Breakdown of Net Sales (%), by Main Products, 2018
FIG. 97 Teleflex Incorporated, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
FIG. 98 Teleflex Incorporated, Breakdown of Net Sales (%), by Business Segment, 2018
FIG. 99 Teleflex Incorporated, Breakdown of Net Sales (%), by Geography, 2018
FIG. 100 Boston Scientific Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2018
FIG. 101 Boston Scientific Corporation Breakdown of Net Sales (%), by Business Segment, 2018
FIG. 102 Boston Scientific Corporation Breakdown of Net Sales (%), by Country, 2017
FIG. 103 Boston Scientific Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018
FIG. 104 Olympus Corporation Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2018
FIG. 105  Olympus Corporation Breakdown of Net Sales (%), by Region, 2018
FIG. 106 Olympus Corporation Breakdown of Net Sales (%), by Medical Business Segment, 2018

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 5795
$ 8795

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top